Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4500-4510

  Ellis, Leigh ^a,k   Pan, Yan ^b   Smyth, Gordon K ^c   George, Daniel J ^e   McCormack, Chris ^a,b,d   Williams Truax, Roxanne ^e   Mita, Monica ^f   Beck, Joachim ^g   Burris, Howard ^h   Ryan, Gail ^a   Atadja, Peter ⁱ   Butterfoss, Dale ⁱ   Dugan, Margaret ^j   Culver, Kenneth ^j   Johnstone, Ricky W ^a,d   Prince, H Miles ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e DUKE UNIVERSITY   (United States)

^f CTRC Institute for Drug Development   (United States)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k Biology and Environment   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PANOBINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EYE SWELLING; FATIGUE; FOLLOW UP; GENE CONTROL; GENE EXPRESSION PROFILING; GENE MUTATION; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MICROARRAY ANALYSIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ACETYLATION; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR;

ACETYLATION; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 51649126841     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4262     Document Type: Article

References (43)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105: 3768-85.
2. Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001;45:700-6.
3. Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneousT-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005;12: 273-8.
4. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25: 84-90.
5. Duvic M, Hymes K, Heald P. et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase ll-lll trial results. J Clin Oncol 2001;19: 2456-71.
6. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.
7. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005;115:798-812
8. Prince HM, McCormack C, Ryan G, O'Keefe R. Seymour JF, Baker C. Management of the primary cutaneous lymphomas. Australas J Dermatol 2003; 44:227-40; quiz 41-2.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
10. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
11. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004;18:2315-35.
12. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001;48 Suppl 1:S17-9.
13. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-78.
14. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
15. Kelly WK, O'Connor OA, Krug LM, et al Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
16. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;2:166-73.
17. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8.
18. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action J Invest Dermatol 2005;125:1045-52.
19. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9.
20. Prince HM, George DJ, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and Non-Hodgkin's lymphoma [abstract 3500]. J Clin Oncol 2007;25.
21. Bolstad BM, Collin F, Brettschneider K, et al. Quality assessment of Affymetrix Gene Chip data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 33-47.
22. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F. Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004;99:909-17.
23. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
24. Ritchie ME, Diyagama D, Neilson J, et al. Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics 2006;7:261.
25. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article 3.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995;57:289-300
27. Gough DJ, Sabapathy K. Ko EY, et al. A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon γ response genes. J Biol Chem 2007;282:938-46.
28. Sandor V, Senderowicz A, Mertins S, et al. P21- dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000;83: 817-25.
29. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5.
30. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97: 10014-9.
31. Piekarz R, Frye R, Wright J, et al. Update of the NCI multiinstitutional phase II trial of romidepsin. FK228. for patients with cutaneous or peripheral T-cell lymphoma [abstract 8027]. J Clin Oncol 2007.25.
32. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6
33. Fiskus W, Pranpat M. Bali P et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Ablexpressing human leukemia cells. Blood 2006;108 645-52.
34. Maiso P. Carvajal-Vergara X, Ocio EM. et al The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res 2006;66:5781-9
35. Catley L, Weisberg E, Kiziltepe T et al. Aggresome induction by proteasome inhibitor bortezomib and α- tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9,
36. Kalff A, Shortt J, Farr J. et al. Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia. Haematologica 2008: 93:e16-7.
37. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Proc Natl Acad Sci U S A 2005;102:3697-702
38. Saino M, Maruyama T Sekiya T Kayama T. Murakami Y. Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3. Oncol Rep 2004:12 47-52.
39. Roccaro AM, Hideshimal Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Res 2006;66:184-91
40. 2/M progression of breast cancer cells by modulating the expression activity of p21 (WAF1/CIP1). cyclin D1, and cdk2. Biochem Biophys Res Commun 2000;270 1144-53.
41. Pereira FA, Qiu Y, Zhou G, Tsai MJ. Tsai SY. The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development Genes Dev 1999;13:1037-49.
42. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
43. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629-35